![](/img/cover-not-exists.png)
PCN87 PHARMACOECONOMIC ANALYSIS OF DIRECT MEDICAL COSTS OF METASTATIC COLORECTAL CANCER THERAPY WITH XELOX OR FOLFOX4 WITH OR WITHOUT BEVACIZUMAB AS THE FIRST-LINE TREATMENT
A Tikhomirova, A Kulikov, R YagudinaVolume:
13
Year:
2010
Language:
english
DOI:
10.1016/s1098-3015(11)71982-9
File:
PDF, 79 KB
english, 2010